MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma

References

• Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894–906. doi:10.1016/S0140-6736(15)00046-X26318520
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.26742998
   PubMed Web of Science ®Google Scholar
• Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84. doi:10.1016/j.eururo.2018.08.03630243799
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924. doi:10.1016/j.eururo.2015.01.00525616710
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.28276433
   PubMed Web of Science ®Google Scholar
• Berger J, Bird A. Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans. 2005;33(Pt 6):1537–1540. doi:10.1042/BST33153716246164
   PubMedGoogle Scholar
• Jablonska E, Reszka E. Selenium and epigenetics in cancer: focus on DNA methylation. Adv Cancer Res. 2017;136:193–234.29054419
   PubMed Web of Science ®Google Scholar
• Jeltsch A, Broche J, Lungu C, Bashtrykov P. Biotechnological Applications of MBD Domain Proteins for DNA Methylation Analysis. J Mol Biol. 2020;432:1816–1823.
   PubMed Web of Science ®Google Scholar
• Sarraf SA, Stancheva I. Retraction notice to: methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell. 2019;73(5):1084. doi:10.1016/j.molcel.2019.02.02330849389
   PubMed Web of Science ®Google Scholar
• Ginder GD, Williams DC. Corrigendum to “Readers of DNA methylation, the MBD family as potential therapeutic targets” [Pharmacology & Therapeutics 184 (1) (2018) 98–111]. Pharmacol Ther. 2018;190:237–238. doi:10.1016/j.pharmthera.2018.09.00630268235
   PubMedGoogle Scholar
• Detich N, Theberge J, Szyf M. Promoter-specific activation and demethylation by MBD2/demethylase. J Biol Chem. 2002;277(39):35791–35794. doi:10.1074/jbc.C20040820012177048
   PubMed Web of Science ®Google Scholar
• Parry L, Clarke AR. The roles of the methyl-CpG binding proteins in cancer. Genes Cancer. 2011;2(6):618–630. doi:10.1177/194760191141849921941618
   PubMedGoogle Scholar
• Mahmood N, Rabbani SA. DNA methylation readers and cancer: mechanistic and therapeutic applications. Front Oncol. 2019;9:489.31245293
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang F, Li S, et al. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression. Br J Haematol. 2014;165(5):649–658. doi:10.1111/bjh.1281124601943
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu Y, Pan X, Li SC, Yang S, Li SC. DNA methylation markers for pan-cancer prediction by deep learning. Genes. 2019;10(10):778. doi:10.3390/genes10100778
   PubMed Web of Science ®Google Scholar
• Mahmood N, Rabbani SA. Targeting DNA hypomethylation in malignancy by epigenetic therapies. Adv Exp Med Biol. 2019;1164:179–196.31576549
   PubMed Web of Science ®Google Scholar
• Pontes TB, Chen ES, Gigek CO, et al. Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis. Tumour Biol. 2014;35(4):3447–3453. doi:10.1007/s13277-013-1455-y24338710
   PubMedGoogle Scholar
• Devailly G, Grandin M, Perriaud L, et al. Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells. Nucleic Acids Res. 2015;43(12):5838–5854. doi:10.1093/nar/gkv50826007656
   PubMed Web of Science ®Google Scholar
• Teslow EA, Mitrea C, Bao B, et al. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells. Mol Oncol. 2019;13(4):894–908. doi:10.1002/1878-0261.1244430636104
   PubMed Web of Science ®Google Scholar
• Yuan K, Xie K, Fox J, et al. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology. 2013;145(4):853–864. doi:10.1053/j.gastro.2013.06.00823770133
   PubMed Web of Science ®Google Scholar
• Zhu D, Hunter SB, Vertino PM, Van Meir EG. Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. Cancer Res. 2011;71(17):5859–5870. doi:10.1158/0008-5472.CAN-11-115721724586
   PubMed Web of Science ®Google Scholar
• Cui S, Liu L, Wan T, Jiang L, Shi Y, Luo L. MiR-520b inhibits the development of glioma by directly targeting MBD2. Am J Cancer Res. 2017;7(7):1528–1539.28744402
   PubMed Web of Science ®Google Scholar
• Chen Y, Luo J, Tian R, Sun H, Zou S. miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci. 2011;56(6):1693–1701. doi:10.1007/s10620-010-1481-121086164
   PubMed Web of Science ®Google Scholar
• Liu W, Wang N, Lu M, Du XJ, Xing BC. MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection. Mol Med Rep. 2016;14(2):1617–1623. doi:10.3892/mmr.2016.540427315121
   PubMed Web of Science ®Google Scholar
• Li C, Li H, Yang J. Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miR-5095 from MBD2. J Cell Physiol. 2019;234(10):18504–18512. doi:10.1002/jcp.2848630912130
   PubMed Web of Science ®Google Scholar
• Cheng L, Tang Y, Chen X, et al. Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells. Cancer Biol Ther. 2018;19(8):676–686. doi:10.1080/15384047.2018.145011329565710
   PubMed Web of Science ®Google Scholar
• Pulukuri SM, Rao JS. CpG island promoter methylation and silencing of 14-3-3σ gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene. 2006;25(33):4559–4572. doi:10.1038/sj.onc.120946216786000
   PubMed Web of Science ®Google Scholar
• Chatagnon A, Bougel S, Perriaud L, Lachuer J, Benhattar J, Dante R. Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis. 2009;30(1):28–34. doi:10.1093/carcin/bgn24018952593
   PubMed Web of Science ®Google Scholar
• Bakker J, Lin X, Nelson WG. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem. 2002;277(25):22573–22580. doi:10.1074/jbc.M20300920011960994
   PubMed Web of Science ®Google Scholar
• Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci U S A. 2001;98(9):4990–4995. doi:10.1073/pnas.10161729811309512
   PubMed Web of Science ®Google Scholar
• Huo FC, Pan YJ, Li TT, Mou J, Pei DS. PAK5 promotes the migration and invasion of cervical cancer cells by phosphorylating SATB1. Cell Death Differ. 2019;26(6):994–1006. doi:10.1038/s41418-018-0178-430082769
   PubMed Web of Science ®Google Scholar
• Alvarado S, Wyglinski J, Suderman M, Andrews SA, Szyf M. Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line. PLoS One. 2013;8(10):e74009. doi:10.1371/journal.pone.007400924204564
   PubMed Web of Science ®Google Scholar
• Karpinski P, Pesz K, Sasiadek MM. Pan-cancer analysis reveals presence of pronounced DNA methylation drift in CpG island methylator phenotype clusters. Epigenomics. 2017;9(11):1341–1352. doi:10.2217/epi-2017-007028960094
   PubMed Web of Science ®Google Scholar
• Jara-Espejo M, Peres Line SR. DNA G-quadruplex stability, position and chromatin accessibility are associated with CpG island methylation. FEBS J. 2020;287:483–495.31532882
   PubMed Web of Science ®Google Scholar
• Sina AA, Carrascosa LG, Trau M. DNA methylation-based point-of-care cancer detection: challenges and possibilities. Trends Mol Med. 2019;29:955–966. doi:10.1016/j.molmed.2019.05.014
   Google Scholar
• Liu Z, Wang Z, Jia E, et al. Analysis of genome-wide in cell free DNA methylation: progress and prospect. Analyst. 2019;144(20):5912–5922. doi:10.1039/C9AN00935C31436778
   PubMed Web of Science ®Google Scholar
• Stirzaker C, Song JZ, Ng W, et al. Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer. Oncogene. 2017;36(10):1328–1338. doi:10.1038/onc.2016.29727593931
   PubMed Web of Science ®Google Scholar
• Spiess BM, Wilcock BP, Physick-Sheard PW. Eosinophilic granulomatous dacryoadenitis causing bilateral keratoconjunctivitis sicca in a horse. Equine Vet J. 1989;21(3):226–228. doi:10.1111/j.2042-3306.1989.tb02153.x2731512
   PubMed Web of Science ®Google Scholar
• Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet. 2003;34(2):145–147. doi:10.1038/ng115512730693
   PubMed Web of Science ®Google Scholar
• Kanai Y, Ushijima S, Nakanishi Y, Hirohashi S. Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem Biophys Res Commun. 1999;264(3):962–966. doi:10.1006/bbrc.1999.161310544038
   PubMed Web of Science ®Google Scholar
• Ye D, Luo H, Lai Z, et al. ClC-3 chloride channel proteins regulate the cell cycle by up-regulating cyclin D1-CDK4/6 through suppressing p21/p27 expression in nasopharyngeal carcinoma cells. Sci Rep. 2016;6:30276. doi:10.1038/srep3027627451945
   PubMed Web of Science ®Google Scholar
• Radine C, Peters D, Reese A, et al. The RNA-binding protein RBM47 is a novel regulator of cell fate decisions by transcriptionally controlling the p53-p21-axis. Cell Death Differ. 2020;27:1274–1285. doi:10.1038/s41418-019-0414-631511650
   PubMed Web of Science ®Google Scholar
• Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019;216(5):1016–1026. doi:10.1084/jem.2018182730975895
   PubMed Web of Science ®Google Scholar
• Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70. doi:10.1186/s12943-019-0994-230927908
   PubMed Web of Science ®Google Scholar